Stockholms Affärsänglar (Stockholm Business Angels) and Almi Invest make capital investment in Inhalation Sciences AB (ISAB)

STOCKHOLM, SWEDEN – June 25, 2015. ISAB is broadening its ownership base: venture finance company Stockholms Affärsänglar (STOAF), together with Almi Invest, become new minority share owners, with a significant initial capital investment. The new ownership and investment reflects ISABs strategy of commercializing its world-leading technology platform for inhalation R&D.

DOWNLOAD PDF: ISAB Press Release 25.06.2015 New Investors

The capital investment, by Stockholms Affärsänglar (STOAF) and Almi Invest, is the first phase of a three-phase investment in ISAB. STOAF is a prestigious Swedish venture finance company and syndicate made up of angel investors. STOAF funds both young, innovative companies and multinationals that have unique skillsets in their field and strong market potential. Almi Invest is an industry-independent venture capital company and Sweden’s most active investor in young growth companies. It focuses on companies with scalable business concepts and solid prospects for long-term capital growth.

Fredrik Sjövall, ISAB CEO: “We see increased possibilities from this broadening of our ownership base. Stockholm Business Angels’ and Almi’s expertise and network will help us realize and speed up the commercialization of our products following the first rollouts of our technology. Getting new owners onboard underlines the growing potential, scalability and exceptional technological caliber of our products.”

STOAF CEO Klaus Gottwald: “With ISAB we have added another medtech venture to our portfolio of companies with a strong science and technology profile. STOAF will contribute to ISAB’s development through new input in both funding and competence. With our strong international network of business contacts we look forward to helping ISAB establish itself in both Asia and the US.”

Almi Invest Investment Manager Claes Post: “Thanks to Inhalation Sciences’ technology platform the costs of developing treatments for a range of lung diseases can be significantly reduced. The consumption of expensive test substances during development can be minimized and the precision of the data generated dramatically improved. The pharmaceutical industry has a great need to reduce their development costs while still producing effective treatments against lung disease.”